following an abbreviated submission:
upadacitinib (Rinvoq®) is accepted for use within NHSScotland.
Indication under review: for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Upadacitinib offers an additional treatment choice in the therapeutic class of immunosuppressants.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice633KB (PDF)
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2532
- Indication:
Treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation (OSI) as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 February 2023